Moreover, Savona et al. investigated an oral fixed-dose combination of decitabine and cedazuridine, i.e., a CDA inhibitor, in patients with myelodysplastic syndromes or chronic myelomonocytic leukemia [17] and demonstrated favorable decitabine PK through inhibition of CDA. The gene discussed is CDA; the disease is chronic myelomonocytic leukemia.